Generic Lenacapavir: FDA Clears the $40 HIV Prevention Shot for 120 Countries
On 2 November 2026, the US Food and Drug Administration gave tentative approval to the first generic version of lenacapavir, a twice-yearly injection that prevents HIV infection. The manufacturer is Dr. Reddy's Laboratories of India, and the number attached to the deal is the one that matters most: about $40 per person per year, against roughly $28,000 a year for the branded drug in the United States. The approval opens a direct path to supply 120 low- and middle-income countries.
Lenacapavir is the first HIV medicine of its class, a capsid inhibitor that attacks the protein shell protecting the virus's genetic material. Its trial results were the kind that reset expectations. In the PURPOSE 1 trial, run across 25 sites in South Africa and Uganda among more than 5,300 cisgender women and adolescent girls, researchers observed zero HIV infections among participants assigned to lenacapavir. A second large trial put overall efficacy above 99.9 percent. The journal Science named the underlying research its Breakthrough of the Year in 2024, and in July 2025 the World Health Organization added twice-yearly lenacapavir to its prevention guidelines.
The word "tentative" does real work here, and it is worth understanding precisely. It means the FDA has judged the generic safe and effective, but patent and exclusivity protections keep it off the American market for now. What tentative approval unlocks is supply to the licensed countries, often through global health programmes. It is a regulatory door built for exactly this situation: a drug too expensive for the places that need it most, approved for those places first.
The speed is also part of the story. The branded drug was approved in the United States only in June 2025; the generic clearance arrived about sixteen months later, through a voluntary licence arranged with Unitaid, the Clinton Health Access Initiative, and the Wits Reproductive Health and HIV Institute, under a pricing agreement struck in September 2025. Dr. Reddy's is the first of six licensed manufacturers to clear FDA review. Initial shipments are slated to reach early-adopter nations, including Zambia, before the end of 2026, with wider rollouts across sub-Saharan Africa, Latin America, and Asia scheduled through 2027.
But approval is not access, and the history of HIV prevention gives good reason to keep those two things apart. Daily oral PrEP has existed for years and never reached most of the people who needed it, held back by adherence, stigma, and clinic access rather than by pharmacology. A twice-yearly injection removes the adherence problem almost entirely: two clinic visits a year instead of a pill every day. What it does not remove is the delivery problem. Each country still needs its own regulatory clearance, procurement, cold chain, trained staff, and outreach to the young women most at risk, plus follow-up to keep them coming back.
That is where this story will actually be decided, and it is a genuinely open question. The machinery behind this approval — the licence, the $40 price, the six manufacturers, the global health buyers — is the most serious delivery apparatus ever assembled for an HIV prevention drug. Whether it converts into injections in arms at scale, and how fast, is the test. My prediction is that generic lenacapavir reaches patients in at least 25 of the 120 licensed countries by the end of 2027: roughly a fifth of the map in about fourteen months. The early shipments to Zambia and other first movers make the first few countries close to certain; the next twenty are where procurement, regulation, and clinic capacity have to work in sequence, and where past PrEP rollouts have usually stalled.
If it clears that bar, the $40 shot will have done something no HIV prevention tool has done before: arrive where the epidemic actually is, at a price those health systems can pay. If it does not, the bottleneck will be visible and named — and that is the next thing to fix.